Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
RNA-lipoplex prostate cancer vaccine
- Development stage
- Unknown
- Lead developer
- BioNTech
- Modality
- mRNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Lipid-based Nanoparticles → Nanoparticles → Drug Delivery Systems, Vaccines & Immunotherapeutics
- Administration
- Intravenous
01
Overview
The RNA-lipoplex prostate cancer vaccine is an investigational mRNA-based immunotherapy developed by Ahvaz Jundishapur University of Medical Sciences. It utilizes an RNA-lipoplex (liposome) delivery system for intravenous administration, encoding three specific prostate cancer-associated antigens: prostatic acid phosphatase (PAP), prostate-specific membrane antigen (PSMA), and six-transmembrane epithelial antigen of the prostate 1 (STEAP1). The vaccine is designed to stimulate a systemic T-cell-mediated immune response against tumor cells expressing these antigens. It is currently being evaluated in Phase I clinical trials for the treatment of prostate cancer.
- Other names
- RNA-liposome prostate cancer vaccine
02
Targets
P fimbriaeSTEAP1 (Six-transmembrane epithelial antigen of prostate 1)PSMA (Prostate-specific membrane antigen)
Beyond the preview
Go deeper on RNA-lipoplex prostate cancer vaccine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on RNA-lipoplex prostate cancer vaccine.